Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSavills Regulatory News (SVS)

Share Price Information for Savills (SVS)

Share Price is delayed by 15 minutes
Get Live Data
811.00    3.00 (0.37%)
Bid:
810.00
Ask:
812.00
Spread: 2.00 (0.247%)
Market Cap: £1.12b
SVS Live PriceLast checked at - London Stock Exchange

Intraday Savills Share Chart

AGM Statement

14 May 2025 07:00

RNS Number : 5368I
Savills PLC
14 May 2025
Β 

14 May 2025

SAVILLS PLC

Β 

("Savills" or "the Company")

Β 

Trading update

Β 

Ahead of its Annual General Meeting (AGM) to be held at 12 noon today at Savills, 33 Margaret Street, London W1G 0JD, Savills plc, the international real estate advisor issues the following trading update:

Β 

Savills has traded broadly in line with our expectations in the first quarter and for the year to date, and comfortably ahead of the comparable period last year.Β 

Β 

Highlights:

Β 

Β· Our global capital transaction revenue improved (+7% in Q1), particularly in EMEA and, with some exceptions, values are largely recalibrated in most prime markets. There is renewed investor interest in prime core office stock throughout Europe.

Β· Leasing revenues grew over 20% in Q1 as markets have continued to be more active across most sectors.

Β· Most prime residential markets have remained resilient through Q1 with the UK performing better than last year in advance of the increase in Stamp Duty.

Β· Savills less transactional businesses (Property Management, Investment Management and Consultancy) have performed as expected, with a particularly strong performance in Consultancy.

Β· The uncertainty created by recent macro-economic and geopolitical events has resulted in a short term slow-down in global transaction activity, which we expect to recover as sentiment becomes more certain.

Β· The Group's underlying pipeline of potential transactions is significantly improved compared with the same time last year.

Β 

Our less transactional businesses continue to provide a solid platform for the Group with a resilient earnings stream. Meanwhile on the transactional side, there remains significant investor interest in the secure income characteristics of real estate, and in most major cities the office market is seeing much greater investor demand.

Β 

Outlook

Β 

We continue to develop our business through selective recruitment and acquisitions, supported by a strong balance sheet.

Β 

We expect that the impact of tariffs on the execution of transactions in Q2 means that Savills H1 performance may be largely similar to last year, however we anticipate continued improvement in market conditions through the second half of the year.

Β 

The Group's Half Year Results for the six months to 30 June will be announced on 14 August 2025.

Β 

Mark Ridley, Chief Executive, commented:

Β 

"We have had a good start to the year with performance comfortably ahead of the prior year, reflecting progressive recovery in most markets. The current macro-level uncertainty is clearly having a near term impact on transactional activity, as investors and corporates digest the potential effects of recent events. However, I am confident that the underlying trajectories for our transactional businesses are substantially improved year-on-year. I am delighted with the performance of our teams worldwide in helping clients navigate these circumstances and in seeking longer term business development initiatives, which our strong balance sheet enables us to pursue."

Β 

Β 

Β 

Β 

For further information, contact:

Β 

Savills 020 7409 8934

Mark Ridley, Group Chief Executive

Simon Shaw, Group Chief Financial Officer

Β 

Teneo 020 7353 4200

Elizabeth Snow

Jo Blackshaw

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
AGMFLFSAEDIVLIE
Date   Source Headline
1st Jun 202611:29 amRNSTotal Voting Rights
22nd May 202610:09 amRNSDirector/PDMR Shareholding
14th May 202612:41 pmRNSResult of AGM
13th May 20264:16 pmRNSResult of AGM
13th May 20267:00 amRNSAGM Statement
12th May 20263:41 pmRNSDirector/PDMR Shareholding
7th May 20263:39 pmRNSDirector Declaration
29th Apr 20263:04 pmRNSReplacement - Director/PDMR Shareholding
29th Apr 20261:23 pmRNSDirector/PDMR Shareholding
28th Apr 20261:58 pmRNSDirector/PDMR Shareholding
13th Apr 20265:24 pmRNSHolding(s) in Company
13th Apr 20262:10 pmRNSDirector/PDMR Shareholding
7th Apr 20264:03 pmRNSAnnual Report and AGM Notice
1st Apr 202610:00 amRNSTotal Voting Rights
31st Mar 202612:55 pmRNSDirector/PDMR Shareholding
26th Mar 20268:57 amRNSDirector/PDMR Shareholding
24th Mar 202611:02 amRNSDirector/PDMR Shareholding
23rd Mar 20269:27 amRNSDirector/PDMR Shareholding
18th Mar 20263:47 pmRNSDirector/PDMR Shareholding
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
13th Mar 20261:34 pmRNSDirector/PDMR Shareholding
13th Mar 20261:32 pmRNSDirector/PDMR Shareholding
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:08 amRNSFinal Results
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
5th Mar 20265:00 pmRNSHolding(s) in Company
2nd Mar 20269:11 amRNSTotal Voting Rights
25th Feb 202611:14 amRNSHolding(s) in Company
11th Feb 20264:07 pmRNSDirector/PDMR Shareholding
4th Feb 20265:29 pmRNSHolding(s) in Company
2nd Feb 20265:32 pmRNSTotal Voting Rights
19th Jan 20268:30 amRNSDirectorship change
15th Jan 20267:00 amRNSYear End Trading Update
13th Jan 20265:40 pmRNSDirector/PDMR Shareholding
13th Jan 202612:59 pmRNSHolding(s) in Company
2nd Jan 20263:00 pmRNSTotal Voting Rights
11th Dec 20252:00 pmRNSDirector/PDMR Shareholding
1st Dec 20259:49 amRNSTotal Voting Rights
11th Nov 20254:58 pmRNSDirector/PDMR Shareholding
3rd Nov 202512:32 pmRNSTotal Voting Rights
13th Oct 20251:33 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.